John Baird, M.D.

800-826-4673
John Baird
Hematologist-Oncologist
313E748E-6769-4B81-8A31-A50681850EB0 Ratings are pending and will be posted once we receive a sufficient number of surveys.
Clinical Expertise
Lymphoma
Leukemia
Bone Marrow and Stem Cell Transplant
Research Area
Immunotherapies for Leukemia and Lymphoma
Appointments
Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Immunotherapy Modality
Leukemia
Lymphoma
John H. Baird, M.D., was drawn to his career as a doctor when he found working with patients to be his favorite part of his initial focus in biomedical engineering. For him, being a physician-researcher is the best of both worlds. He provides innovative therapies and his own brand of compassionate care to people with leukemia and lymphoma, while also advancing the state of the field in cancer treatment and improving patient outcomes with clinical research.
 
Dr. Baird pursued his medical training at the University of Arkansas, then served as an intern and resident at the University of Pennsylvania and a fellow at Stanford University, where he specialized in medical oncology, hematology, and blood and marrow transplantation. His research concerns next-generation cellular therapies for blood diseases, including CAR T cell therapy, in which a patient's own immune cells are engineered to seek and destroy cancer.
Location
Education & Experience
Board Certifications

  • Hematology

  • Medical Oncology

  • Internal Medicine

Degrees

  • 2013, M.D., University of Arkansas for Medical Sciences, Little Rock, AR

  • 2008, B.S., Biomedical Engineering, Washington University, St. Louis, MO

Fellowship

  • 2020-2021, Fellow, Blood and Marrow Transplantation, Stanford Hospital & Clinics, Palo Alto, CA

  • 2019-2020, Postdoctoral Fellow, Cancer Cellular Therapies, Stanford University, Palo Alto, CA

  • 2016-2019, Fellow, Hematology and Medical Oncology, Stanford Hospital & Clinics, Palo Alto, CA

Residency

  • 2014-2016, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Internship

  • 2013-2014, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Professional Experience

  • 2021-resent, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Awards & Memberships
Awards

  • 2020, Abstract Achievement Award, American Society of Hematology

  • 2019, NIH T32 Institutional Training Grant, Stanford, Department of BMT

  • 2013, Richard V. Ebert Award, UAMS, Department of Internal Medicine

  • 2013, Graduated with Honors in Research, UAMS

  • 2012, Class of 1949 Scholarship, UAMS

  • 2012, Clinical Research Training Program Fellow, NIH-OCRTME

  • 2011, Alpha Omega Alpha, UAMS

  • 2010, Barton Foundation Scholarship, UAMS

  • 2010, Dr. George S. Wise Memorial Scholarship, UAMS

  • 2009, Class of 1954 Scholarship, UAMS

  • 2009, Medical Student Research Program in Diabetes, NIDDK

  • 2008, Medical Alumni Association Scholarship, UAMS

  • 2008, Dorothy Snider Foundation Scholarship, UAMS

  • 2003, Eagle Scout, Bronze and Gold Eagle Palms, BSA QAC Troop 7

Memberships

  • American Society for Transplantation and Cellular Therapy

  • American Society of Hematology, Associate Member

  • American Society of Clinical Oncology

  • CIBMTR Infection and Immune Reconstitution Working Group

  • American College of Physicians

Publications
  • Baird JH, Frank MJ, Craig J, et al.: “CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.” Blood. 2021; doi: 10.1182/blood.2020009432.
  • Spiegel JY, Patel S, Muffly L, Hossain N, Oak J, Baird JH, et al.: “Dual targeting CD19/CD22 chimeric antigen receptor T cells in adults with recurrent or refractory B cell malignancies.” Nat Med. 2020 in submission.
  • Johnsrud AJ, Craig J, Baird JH, et al. “Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy.” Blood Adv. 2021; doi: 10.1182/bloodadvances.2021004716.
  • Baird JH, Epstein DJ, Tamaresis JS, et al.: “Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.” Blood Adv. 2021; 5(1):143-55.
  • Van Vuren AJ, Minniti CP, Mendelsohn L, Baird JH, et al.: “Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in SCD.” Am J
  • Baird JH, Gotlib J, George TI, et al.: “A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.” Blood Adv. 2019 Aug 13;3(15):2264-2271.
  • Baird JH, Gotlib J: “Clinical validation of KIT inhibition in advanced systemic mastocytosis.” Curr Hematol Malig Rep. 2018 Oct;13(5):407-416.
  • Baird JH, Minniti CP, Lee JM, Tian X, et al.: “Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.” Br. J. Haematol. 2015; 168(5):737-46. 7.
  • Baird JH, Frey N, Birnbaum B, Porter DL: “Voriconazole-induced periostitis after allogeneic stem cell transplantation.” Am. J. Hematol. 2015; 90(6):574-5.
  • Lodhi IJ, Yin L, Coleman T, Baird JH, et al.: “Targeted inhibition of adipose lipogenesis decreases obesity and insulin resistance by disrupting PPAR-γ activation.” Cell Metab. 2012; 16(2):189-201.